Core Viewpoint - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration of China for its microcatheter V-otter, which is designed for use in peripheral and coronary vascular interventional procedures, leading to a stock price increase of over 5% during trading [1]. Company Summary - Xianruida Medical-B's stock price rose by 3.25% to HKD 13.01, with a trading volume of HKD 2.4495 million [1]. - The V-otter microcatheter is specifically designed for transcatheter arterial chemoembolization (TACE) procedures, featuring a large lumen design to effectively prevent catheter blockage during operations [1]. - The product offers three types of tip configurations: straight, 45° single bend, and multiple bends, allowing for adaptability to various clinical needs and precise access to target blood vessels [1].
港股异动 先瑞达医疗-B(06669)盘中涨超5% 近日微导管V-otter注册申请获批